This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Borneol
- DrugBank Accession Number
- DB11288
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Borneol (DB11288)
- Weight
- Average: 154.2493
Monoisotopic: 154.135765198 - Chemical Formula
- C10H18O
- Synonyms
- Borneo camphor
- Bornyl alcohol
- endo-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
- endo-2-bornanol
- endo-2-camphanol
- endo-2-hydroxycamphane
- Sumatra camphor
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hundred Koyok Classic Borneol (0.18 mg) + Camphor (0.41 mg) + Levomenthol (0.62 mg) + Methyl salicylate (0.62 mg) + Thymol (0.04 mg) Plaster Transdermal JWP Medical Sdn. Bhd. 2020-09-08 Not applicable Malaysia 
HundredPlast Koyok Borneol (0.18 mg) + Camphor (0.41 mg) + Levomenthol (0.62 mg) + Methyl salicylate (0.62 mg) + Thymol (0.04 mg) Patch Topical TEONG HUAT MEDICAL SDN. BHD. 2020-09-08 Not applicable Malaysia HUNDREDPLAST KOYOK CLASSIC Borneol (1.5 %w/w) + Camphor (3 %w/w) + Levomenthol (6.5 %w/w) + Methyl salicylate (6.5 %w/w) + Thymol (0.5 %w/w) Plaster Transdermal THP MEDICAL SDN. BHD. 2020-09-08 Not applicable Malaysia Kwan Tak Hing Plaster - Pad-pls Borneol (1.75 g / pad) + Levomenthol (3.5 g / pad) Plaster; Swab Topical Wing Quon Enterprises Ltd. 1996-08-16 1998-08-12 Canada 
La Jiao Feng Shi Gao Borneol (3.0 g/100g) + Levomenthol (3.0 g/100g) Plaster Transdermal Henan Lingrui Pharmaceutical Co.; Ltd 2010-06-02 2014-03-11 US 
Ma Ying Long Hemorrhoidal Borneol (0.2 g/10g) + Amber (0.1 g/10g) + Bos taurus gallstone (0.1 g/10g) + Moschus berezovskii musk sac resin (0.15 g/10g) + Pearl (hyriopsis cumingii) (0.25 g/10g) + Sodium borate decahydrate (0.2 g/10g) + Zinc carbonate (0.65 g/10g) Ointment Topical Trifecta Pharmaceuticals Usa, Llc. 2016-01-14 Not applicable US Neobun Medicated Plaster with Ginger and Lemongrass Oil Aroma Borneol (0.18 mg) + Camphor (0.34 mg) + Levomenthol (0.41 mg) + Thymol (0.04 mg) Plaster Topical TEONG HUAT MEDICAL SDN. BHD. 2020-09-08 Not applicable Malaysia Pain Free Borneol (0.02 g/1g) + Menthol (0.02 g/1g) + Methyl salicylate (0.01 g/1g) Ointment Topical Albert Max, Inc. 2005-11-01 2016-03-31 US ROWACHOL CAPSULES Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + Menthone (6 mg) + Olive oil (33 mg) + alpha-Pinene (17 mg) Capsule Oral DCH AURIGA (MALAYSIA) SDN. BHD. 2020-09-08 Not applicable Malaysia Salonpas Medicated Plaster Borneol (2 %) + Camphor (2 %) + Diphenhydramine (.8 %) + Levomenthol (6.9 %) + Methyl salicylate (6.9 %) + Olive oil (.7 %) + Rosin (20.5 %) + Thymol (1.4 %) + Zinc oxide (17.8 %) Plaster Topical Hisamitsu Pharmaceutical Co., Inc. 1955-12-31 2002-06-12 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Ma Ying Long Hemorrhoidal Borneol (0.2 g/10g) + Amber (0.1 g/10g) + Bos taurus gallstone (0.1 g/10g) + Moschus berezovskii musk sac resin (0.15 g/10g) + Pearl (hyriopsis cumingii) (0.25 g/10g) + Sodium borate decahydrate (0.2 g/10g) + Zinc carbonate (0.65 g/10g) Ointment Topical Trifecta Pharmaceuticals Usa, Llc. 2016-01-14 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- M89NIB437X
- CAS number
- 507-70-0
- InChI Key
- DTGKSKDOIYIVQL-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3
- IUPAC Name
- 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
- SMILES
- CC1(C)C2CCC1(C)C(O)C2
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Unknown Status Treatment Intracranial Hemorrhages / Stroke, Acute 1 0 Completed Treatment Chronic Stable Angina Pectoris 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Patch Topical Plaster; swab Topical Plaster Transdermal Ointment Topical Capsule Oral Plaster Topical Spray Topical Plaster Capsule, gelatin coated Oral Ointment Liquid Dental Solution Oral Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.805 mg/mL ALOGPS logP 2.83 ALOGPS logP 1.99 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 19.6 Chemaxon pKa (Strongest Basic) -0.78 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 20.23 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 45.31 m3·mol-1 Chemaxon Polarizability 18.48 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Mass Spectrum (Electron Ionization) MS splash10-0002-9200000000-66036eb28e5b6b9f86e6 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at December 03, 2015 16:52 / Updated at June 12, 2020 16:53